Shea Murtaugh is the founder and president of Hoffmann Murtaugh, the largest media-only agency in Pittsburgh.
Shea started her company in 2004 with no capital and now leads a team of 30 people. Prior to funding Hoffman Murtaugh, Shea broke into media via broadcast sales. She’s sold every major form of media over her decorated career and blends that experience into a cocktail that delivers wins for clients.
In this conversation, Shea and Aaron discuss how she got her start, when to hire vs train new talent, and the degree to which she has to be the “banker” of marketing.
Sign up for a Weekly Email that will Expand Your Mind.
Shea Murtaugh’s Challenge; Journal for 5 minutes each day your ideal day one year in the future.
If you liked this interview, check out episode 418 with Marco Marandiz where we discuss how to market in the modern age, what makes an authentic brand, and the future of commerce.
Text Me What You Think of This Episode 412-278-7680
Underwritten by Piper Creative
Piper Creative makes creating podcasts, vlogs, and videos easy.
How? Click here and Learn more.
We work with Fortune 500s, medium-sized companies, and entrepreneurs.
Follow Piper as we grow
Dr. Dietrich Stephan is a geneticist, entrepreneur, and CEO of NeuBase Therapeutics. Neubase is biotech startup focused on developing precision genetic medicines.
Dietrich previously founded or co-founded 14 biotechnology companies, was the chair of the Human Genetics department at the University of Pittsburgh, and was the CEO of LifeX Labs, a biotechnology incubator.
Neubase, his latest company, is developing technology spun out of Carnegie Mellon University that aims to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules.
In April 2021 Neubase went public, trading under the ticker symbol NBSE, and has raised over $100 million in less than three years.
In this conversation, Dietrich and Aaron discuss why Neubase went public earlier than most biotech startups, the vicious diseases they are fighting against, and the impact of the Human Genome Project on society.
Sign up for a Weekly Email that will Expand Your Mind.
Dietrich Stephan’s Challenge;
If you liked this interview, check out episode XX with Craig Markovitz where we discuss business building, university technology transfer, and life after a successful startup.
Text Me What You Think of This Episode 412-278-7680
Underwritten by Piper Creative
Piper Creative makes creating podcasts, vlogs, and videos easy.
How? Click here and Learn more.
We work with Fortune 500s, medium-sized companies, and entrepreneurs.
Follow Piper as we grow
Jonathan Steckbeck is the founder of Peptilogics, a biotechnology platform company that develops best-in-class novel peptide drugs for unmet medical needs. He also has a PhD in Biochemistry and Molecular Genetics from the University of Pittsburgh’s School of Medicine.
Amongst other problems, his company Peptilogics is focused on developing a new category of antibiotics. It has been 20 years since there was a genuinely new class of antibiotics, yet bacterial cells have continued to evolve and develop into drug-resistant infections.
In this interview, Jonathan and Aaron discuss the founding of Peptilogics, why they’re focused on this new modality of medication, and the FDA approval process.
Sign up for a Weekly Email that will Expand Your Mind.
Jonathan Steckbeck’s Challenge; If there’s something that you want to do that doesn’t exist, go do it.
If you liked this interview, check out episode 456 with Pete DeComo where we discuss the long, arduous process of developing a medical device and episode 443 with Blake Dube where we talk about better oxygen tanks.
Text Me What You Think of This Episode 412-278-7680
Underwritten by Piper Creative
Piper Creative makes creating podcasts, vlogs, and videos easy.
How? Click here and Learn more.
We work with Fortune 500s, medium-sized companies, and entrepreneurs.
Follow Piper as we grow
Euan Guttridge is the Director of Technical Program Management at Waymo and previously held the same position with Uber’s self-driving car division.
Between these two roles, Euan developed an angel investing syndicate under the banner Reinforced Ventures. The syndicate differentiates itself for the technical proficiency of its limited partners, bringing a fresh perspective to the companies it invests in.
Euan’s portfolio includes a number of past Going Deep podcast guests including; Gridwise, Locomation, UpContent, Fifth Season, Edge Case Research, and Honeycomb Credit. While not geographically exclusive, Reinforced does focus on Pittsburgh because of its over $10 billion of academic research funded and $6.6 billion of private funding in technology over the past decade.
In this conversation, Euan and Aaron discuss a career developing autonomous vehicle technology, how an AngelList syndicate works, and how to do thorough due diligence.
Sign up for a Weekly Email that will Expand Your Mind.
Euan Guttridge’s Challenge; Follow your curiosity.
If you liked this interview, check out some of Euan’s portfolio companies like Locomation’s Çetin Meriçli, Edge Case Research’s Mike Wagner, and Gridwise’s Ryan Green.
Text Me What You Think of This Episode 412-278-7680
Underwritten by Piper Creative
Piper Creative makes creating podcasts, vlogs, and videos easy.
How? Click here and Learn more.
We work with Fortune 500s, medium-sized companies, and entrepreneurs.
Follow Piper as we grow